Indaptus Therapeutics Stock
Indaptus Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Junyi Dai
- Employees
- 5
- Market cap
- $298 M
- IPO
- 04/08/2015
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.…
Indaptus Therapeutics stock: price history
1D
-7.7%
1W
+4.8%
1M
-18.1%
6M
-23.8%
YTD
-9.6%
1Y
-23.3%
2Y
-93.4%
5Y
-98.8%
10Y
-100.0%
Next earnings date
Next earnings date
17/11/2026 (in 31 days)
Volatility around earnings
~6% weaker price swings than usual
Ask the agents about Indaptus Therapeutics
Analyst assessment of Indaptus Therapeutics
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 13/11/2024
Indaptus Therapeutics stock metrics
P/E
-0.38
P/B
26.86
EV/EBITDA
-18.79
RETURN ON EQUITY
-15.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
3.6%
FLOAT SHARES
4,024,620
AVG. DAILY VOLUME (30D)
1,247,463
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Indaptus Therapeutics stock
What does Indaptus Therapeutics do?
Indaptus Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Junyi Dai, the company employs around 5 people.
The IPO was on 04/08/2015; the stock trades on NASDAQ under the ticker INDP.
What do analysts say about Indaptus Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 13/11/2024).
This is an external assessment, not a statement by Market Jury.
When does Indaptus Therapeutics report next?
The next earnings date is 17/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does Indaptus Therapeutics pay a dividend?
No, Indaptus Therapeutics currently does not pay a dividend.
Which stocks are comparable to Indaptus Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Indaptus Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Indaptus Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.